Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)-- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback